Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

Sorafenib (SOR), an inhibitor of multiple kinases, is a classic targeted drug for advanced hepatocellular carcinoma (HCC) which often coexists with type 2 diabetes mellitus (T2DM). Dapagliflozin (DAPA), a sodium–glucose cotransporter-2 inhibitor (SGLT2i), is widely used in patients with T2DM. Notabl...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Xueru He, Ying Li, Yinling Ma, Yuhao Fu, Xuejiao Xun, Yanjun Cui, Zhanjun Dong
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2022-09-01
Cyfres:	Molecules
Pynciau:	UPLC-MS/MS sorafenib dapagliflozin pharmacokinetics drug–drug interactions
Mynediad Ar-lein:	https://www.mdpi.com/1420-3049/27/19/6190
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!